Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient. Yet, cannabis is still rarely offered for treatment of pain. This clinical trial aimed at showing the positive benefit-risk ratio of dronabinol. Two hundred forty MS patients with central NP entered a 16-weeks placebo-controlled phase-III study followed by a 32-weeks open-label period. One hundred patients continued therapy for overall up to 119 weeks. Primary endpoint was change of pain intensity on the 11-point Numerical Rating Scale over a 16-weeks treatment period. Safety was assessed on the basis of adverse reactions (ARs), signs of dependency and abuse. Pain intensity during 16-weeks dronabinol and placebo treatment was reduced by 1.92 and 1.81 points without significant difference in between (p = 0.676). Although the proportion of patients with ARs was higher under dronabinol compared to placebo (50.0 vs. 25.9%), it decreased during long-term use of dronabinol (26%). No signs of drug abuse and only one possible case of dependency occurred. The trial results demonstrate that dronabinol is a safe long-term treatment option.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Bullinger, M. (1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00115-n · Cited by 763
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Cited by
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Moisset, X., Bouhassira, D., Avez Couturier, J., Alchaar, H., Conradi, S., Delmotte, M. H., Lanteri-Minet, M., Lefaucheur, J. P., Mick, G., Piano, V., et al. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.361 · Cited by 450
Wang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 300
“…et al 2006 Nurmikko et al 2007 Selvarajah et al 2010 Novotna et al 2011 Zajicek et al 2012 Langford et al 2013 Andresen et al 2016 Germini et al 2017 Schimrigk et al 2017 de Vries et al 2017 Subtotal: P=0.021; I2=48.7% Chronic cancer related pain Portenoy et al 2012 Subtotal: P= ; I2= % Overall:…”
BackgroundInfluentialCannabinoid Delivery Systems for Pain and Inflammation Treatment
Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018) · Molecules · doi:10.3390/molecules23102478 · Cited by 272
“Although the proportion of patients that showed adverse reactions was higher in dronabinol-treated than in placebo-treated patients, it decreased over the drug’s long-term use [57,58].”
BackgroundFisher, E., Moore, R. A., Fogarty, A. E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E., Rice, A. S. C., Rowbotham, M., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000001929 · Cited by 215
“One further study conducted a single-dose crossover trial including cannabis and placebo in participants with MS.6 Only one trial included participants with a minimum pain intensity score.79”
BackgroundMethodInfluentialHäuser, W., Finn, D. P., Kalso, E., Krcevski‐Skvarc, N., Kress, H., Morlion, B., Perrot, S., Schäfer, M., Wells, C., & Brill, S. (2018) · European Journal of Pain · doi:10.1002/ejp.1297 · Cited by 199
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Cannabis-Based Products for Chronic Pain: A Systematic Review
McDonagh, M. S., Morasco, B. J., Wagner, J., Ahmed, A. Y., Fu, R. F., Kansagara, D. L., & Chou, R. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4520 · Cited by 173
“…n/N VP NPP FM NPP NPP 15–24 13 EP 2 TD 2 Moderate Low Moderate Moderate Favors intervention 1610.063 Favors control THC-toCBD Ratio Intervention Type Synthetic de Vries et al, 2017* (22) Schimrigk et al, 2017 (31) Skrabek et al, 2008 (34) Turcotte et al, 2015 (36) Subgroup PL (P = 0.69, I2 = 0.0”
BackgroundInfluentialMedical cannabis or cannabinoids for chronic pain: a clinical practice guideline
Busse, J. W., Vankrunkelsven, P., Zeng, L., Heen, A. F., Merglen, A., Campbell, F. A., Granan, L., Aertgeerts, B., Buchbinder, R., Coen, M., et al. (2021) · BMJ · doi:10.1136/bmj.n2040 · Cited by 198
Cannabis for Chronic Pain: Challenges and Considerations
Romero-Sandoval, E. A., Fincham, J. E., Kolano, A. L., Sharpe, B. N., & Alvarado-Vazquez, P. A. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2115 · Cited by 174
“In this 48-week study, dronabinol did not show superiority to placebo for pain intensity.(43) Interestingly, dronabinol-induced side effects were higher than for placebo but were reduced after 4 weeks of administration, suggesting that tolerance could be developed in a relatively short time when pure THC is given oral…”
BackgroundResultCannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
Johal, H., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., & Bhandari, M. (2020) · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · doi:10.1177/1179544120906461 · Cited by 105
Jesus, C. H. A., Redivo, D. D. B., Gasparin, A. T., Sotomaior, B. B., de Carvalho, M. C., Genaro, K., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., Zanoveli, J. M., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2019.03.014 · Cited by 116
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain
Petzke, F. W., Tölle, T. R., Fitzcharles, M., & Häuser, W. (2021) · CNS Drugs · doi:10.1007/s40263-021-00879-w · Cited by 139
““Mild signs” of drug dependency were documented for one participant [26].”
BackgroundGedin, F., Blomé, S., Pontén, M., Lalouni, M., Fust, J., Raquette, A., Lundqvist, V. V., Thompson, W. H., & Jensen, K. B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.43848 · Cited by 105
“…Moderate Low Moderate Low Moderate Nurmikko, 2007 25 Low Low Low Low Moderate Low Moderate Rog, 2015 22 Low Low Low Low Moderate Moderate Moderate Schimrigk, 2017 18 Low Low Low Low Moderate Moderate Moderate Skrabek, 2008 19 Moderate Moderate Moderate Moderate High Moderate High Toth 2012 20…”
BackgroundMaayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165771 · Cited by 111
Endocannabinoid System: Chemical Characteristics and Biological Activity
Rezende, B., Alencar, A. K. N., de Bem, G. F., Fontes-Dantas, F. L., & Montes, G. C. (2023) · Pharmaceuticals · doi:10.3390/ph16020148 · Cited by 121
Zeraatkar, D., Cooper, M. A., Agarwal, A., Vernooij, R. W. M., Leung, G., Loniewski, K., Dookie, J., Ahmed, M. M., Hong, B. Y., Hong, C. J. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054282 · Cited by 97
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain
Blanton, H. L., Brelsfoard, J., Deturk, N., Pruitt, K., Narasimhan, M., Morgan, D. J., & Guindon, J. (2019) · Drugs · doi:10.1007/s40265-019-01132-x · Cited by 75
Safety Considerations in Cannabinoid-Based Medicine
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D’Agnone, O., Schecter, D., Rodríguez, L. D. S., Yafai, S., & Cyr, C. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s275049 · Cited by 73
Effects of cannabinoid administration for pain: A meta-analysis and meta-regression.
Yanes, J. A., McKinnell, Z. E., Reid, M. A., Busler, J. N., Michel, J. S., Pangelinan, M. M., Sutherland, M. T., Younger, J., González, R., & Robinson, J. L. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000281 · Cited by 74
“Author Year Details Regarding Sampled Studies Administration Dose Route Pain Population Pain Measure Scale 17 Schimrigk et al. 2017 Synthtic (Nabilone) 7.5 mg – 15.0 mg Capsule Multiple Sclerosis Numeric Rating Scale 0 – 10 18 Selvarajah et al. 2010 Extract (Sativex) 2.7 mg THC / 2.5 mg…”
BackgroundInfluentialJones, É., & Vlachou, S. (2020) · Molecules · doi:10.3390/molecules25214930 · Cited by 60
“Adverse Event [69] [70] [71] [72] [73] [74] [75] [76] Total”
BackgroundCannabis based medicines and cannabis dependence: A critical review of issues and evidence
Schlag, A. K., Hindocha, C., Zafar, R. R., Nutt, D. J., & Curran, H. V. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986393 · Cited by 78
Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment
Campos, R. M. P., Aguiar, A. F. L., Paes-Colli, Y., Trindade, P. M. P., Ferreira, B. K., Reis, R. A. D. M., & Sampaio, L. D. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.785176 · Cited by 71
The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12050682 · Cited by 78
Siddiqui, S. A., Singh, P., Khan, S., Fernando, I., Baklanov, I. S., Ambartsumov, T. G., & Ibrahim, S. A. (2022) · Sustainability · doi:10.3390/su141710993 · Cited by 63
Jeddi, H. M., Busse, J. W., Sadeghirad, B., Levine, M., Zoratti, M. J., Wang, L., Noori, A., Couban, R., & Tarride, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2022-068182 · Cited by 69
Maayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Inflammation Research · doi:10.1007/s00011-020-01341-1 · Cited by 63
The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials
Bajtel, Á., Kiss, T., Tóth, B., Kiss, S., Hegyi, P. J., Vörhendi, N., Csupor‐Löffler, B., Gede, N., Hohmann, J., & Csupor, D. (2022) · Pharmaceuticals · doi:10.3390/ph15010100 · Cited by 63
“Dronabinol Dronabinol was studied in 10 rando ized, placebo-controlled trials, performed in Canada (n = 1) [25], in Denmark (n = 1) [19], in Germany (n = 1) [12], in the Netherlands (n = 3) [7,16,21], in the USA (n = 3) [8–10] and in the United Kingdom (n = 1) [17], and two of these trials were crossover trials [7–21].”
BackgroundResultInfluentialManaging Chronic Neuropathic Pain: Recent Advances and New Challenges
Hange, N., Poudel, S., Ozair, S., Paul, T., Nambakkam, M., Shrestha, R., Greye, F., Shah, S., Adhikari, Y. R., Thapa, S., et al. (2022) · Neurology Research International · doi:10.1155/2022/8336561 · Cited by 67
“A randomized, doubleblind, placebo-controlled parallel-group design for 16 weeks was followed by a 32 weeks open-label period [53].”
BackgroundMethodInfluentialCentral Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies
Gurba, K. N., Chaudhry, R., & Haroutounian, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00914-4 · Cited by 52
“Another recent systematic review [188] evaluated a total of 36 studies, three of which focused on the effects of cannabinoids on neuropathic pain associated with MS [193, 194, 196].”
BackgroundBarakji, J. A., Korang, S. K., Feinberg, J. B., Maagaard, M., Mathiesen, O., Gluud, C. N., & Jakobsen, J. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0267420 · Cited by 54
“Length of maximum follow-up of the included trials varied between 7 hours [71] and 16 weeks [92] with a mean length of follow-up of 7.”
BackgroundCannabinoids in the Older Person: A Literature Review
Beedham, W., Sbai, M., Allison, I., Coary, R., & Shipway, D. (2020) · Geriatrics · doi:10.3390/geriatrics5010002 · Cited by 40
“However, other trials have not been able to reproduce these results over a longer follow up period [22].”
BackgroundResultHansen, J. S., Gustavsen, S., Roshanisefat, H., Kant, M., Biering‐Sørensen, F., Andersen, C. Y., Olsson, A., Chow, H. H., Asgari, N., Hansen, J. R., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081079 · Cited by 41
Cannabis and multiple sclerosis
Fragoso, Y. D., Carrá, A., & Macias, M. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1776610 · Cited by 45
Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy
Tamba, B.-I., Stanciu, G. D., Urîtu, C. M., Rezuş, E., Ştefănescu, R., Mihai, C. T., Luca, A., Rusu-Zota, G., Leon, M. M., Cojocaru, E., et al. (2020) · Medicina · doi:10.3390/medicina56010024 · Cited by 36
“Dronabinol, a synthetic THC compound with oral administration, was successfully tested both as an analgesic [9] and as a co‐analgesic with opioids [10], amitriptyline, gabapentin or tramadol [11] in clinical studies.”
BackgroundPharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis
Stefano, G. D., Lionardo, A. D., Pietro, G. D., Cruccu, G., & Truini, A. (2021) · Pain Research and Management · doi:10.1155/2021/6656863 · Cited by 41
“In the two RCTs involving patients with multiple sclerosis [28, 29], tetrahydrocannabinol (THC) did not significantly reduce pain in comparison with placebo.”
BackgroundMedicinal Cannabis and Central Nervous System Disorders
Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 33
de Oliveira, R. A. A., Baptista, A. F., Sá, K. N., Barbosa, L. M., Nascimento, O. J. M., Listik, C., Moisset, X., Teixeira, M. J., & de Andrade, D. C. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20200166 · Cited by 32
The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases
Tudorancea, I. M., Ciorpac, M., Stanciu, G. D., Caratașu, C.-C., Săcărescu, A., Ignat, B. E., Burlui, A., Rezuş, E., Creangă-Murariu, I., Alexa‐Stratulat, T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102492 · Cited by 33
Ueberall, M. A., Essner, U., Silván, C. V., & Mueller-Schwefe, G. H. (2022) · Journal of Pain Research · doi:10.2147/jpr.s340968 · Cited by 26
“In a RCT of DRO in 240 patients with neuropathic pain, common ADRs were dizziness, vertigo, fatigue, and dry mouth, occurring most often in the initial 4 weeks of treatment during up-titration to the maximum tolerable dose.(26) The FDA’s Prescribing Information for DRO lists dizziness, euphoria, paranoid reaction, som…”
BackgroundResultAlkislar, I., Miller, A. R., Hohmann, A. G., Sadaka, A. H., Cai, X., Kulkarni, P., & Ferris, C. F. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.11.015 · Cited by 30
“While dronabinol, a purified oral THC, is ineffective in treating neuropathic pain associated with multiple sclerosis (57), Sativex was suggested to be effective in treating multiple sclerosis-induced hyperalgesia and allodynia (58–60).”
BackgroundPereira, S. R., Velasquez, J. T., Duggan, S., Ivanisevic, B., McKenna, J. P., McCreary, C., & Downer, E. J. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14712 · Cited by 30
“Phase III studies assessing neuropathic pain symptoms in MS demonstrate a clinically relevant decrease in pain during a 16-week Marinol® treatment period, when compared to placebo (Schimrigk et al., 2017).”
BackgroundCannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis
Khan, H., Ghori, F. K., Ghani, U., Javed, A., & Zahid, S. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07223-5 · Cited by 27
“The three notable synthetic cannabis-related drug products are Marinol® [oral dronabinol; synthetic Δ9-tetrahydrocannabinol (THC)], Cesamet® [oral nabilone; synthetic Δ9-tetrahydrocannabinol (THC)], Sativex® [oromucosal spray nabixiomls; ~ 1:1 (w/w) combination of tetrahydrocannabinol (THC)] and cannabidiol buccal spr…”
BackgroundChronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option?
Zieglgänsberger, W., Brenneisen, R., Berthele, A., Wotjak, C. T., Bandelow, B., Tölle, T. R., & Lutz, B. (2022) · Medical Cannabis and Cannabinoids · doi:10.1159/000522432 · Cited by 25
Theerasuwipakorn, N., Prechawat, S., Chokesuwattanaskul, R., Siranart, N., Marsukjai, A., Thumtecho, S., & Rungpradubvong, V. (2023) · Toxicology Reports · doi:10.1016/j.toxrep.2023.04.011 · Cited by 28
Stasiłowicz-Krzemień, A., Nogalska, W., Maszewska, Z., Maleszka, M., Dobroń, M., Szary, A., Kępa, A., Żarowski, M., Hojan, K., Łukowicz, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115749 · Cited by 35
“Schimrigk et al. conducted a clinical trial on 240 patients aged 18–70 years with stable multiple sclerosis and moderate to severe central neuropathic pain [293].”
BackgroundJohal, H. S., Vannabouathong, C., Chang, Y., Zhu, M. T., & Bhandari, M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20937968 · Cited by 21
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson, J. L., Bilbrey, J. A., Felix, J. S., Makriyannis, A., & McMahon, L. R. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173192 · Cited by 21
Correia, B., Fernandes, J., Botica, M. J., Ferreira, C., & Quintas, A. (2022) · Medicines · doi:10.3390/medicines9030019 · Cited by 27
“However, despite its synthetic origin, the dronabinol pharmacological active ingredient is ∆9-THC [59].”
BackgroundTetrahydrocannabinol and Cannabidiol for Pain Treatment—An Update on the Evidence
Safi, K., Sobieraj, J., Błaszkiewicz, M., Żyła, J., Salata, B., & Dzierżanowski, T. (2024) · Biomedicines · doi:10.3390/biomedicines12020307 · Cited by 27
Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions
Woo, J., van Reekum, E. A., Rosic, T., & Samaan, Z. (2020) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s254264 · Cited by 19
Bellomo, T. R., Schrepf, A., Kruger, G. H., Lumley, M. A., Schubiner, H. H., Clauw, D. J., Williams, D. A., & Harte, S. E. (2020) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000829 · Cited by 21
Moreno‐Sanz, G., Madiedo, A., Hernandez, P., Kratz, J. W., Aizpurua‐Olaizola, O., Brown, M. R. D., Lopez, J., Patiño, J., & Mendivelso, F. O. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.854795 · Cited by 18
“This observation is intriguing considering that the available medical evidence on cannabinoid therapeutics supports the efficacy of THC-containing products for the treatment of pain (23, 24).”
BackgroundHansen, J. S., Hansen, R. M., Petersen, T., Gustavsen, S., Oturai, A. B., Sellebjerg, F. T., Sædder, E. A., Kasch, H., Rasmussen, P. V., Finnerup, N. B., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11091212 · Cited by 16
Cannabis constituents for chronic neuropathic pain; reconciling the clinical and animal evidence
Sokolaj, E. E., Assareh, N., Anderson, K. E., Aubrey, K. R., & Vaughan, C. W. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15964 · Cited by 18
“Interestingly, another study has shown that oral dronabinol did not produce a significant reduction in multiple sclerosis-related pain until 10 weeks after commencing treatment (Schimrigk et al., 2017 ).”
Moore, A., Karadag, P., Fisher, E., Crombez, G., Straube, S., & Eccleston, C. (2024) · Pain · doi:10.1097/j.pain.0000000000003140 · Cited by 25
Mohiuddin, M. M., Mizubuti, G. B., Haroutounian, S., Smith, S. M., Rice, A. S. C., Campbell, F. A., Park, R., & Gilron, I. (2020) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000807 · Cited by 16
Ueberall, M. A., Horlemann, J., Schürmann, N., Kalaba, M., & Ware, M. A. (2022) · Pain Medicine · doi:10.1093/pm/pnac010 · Cited by 15
“In a randomized controlled trial (RCT) in patients with neuropathic pain due to multiple sclerosis, clinically relevant pain reduction was observed (on an 11-point numerical rating scale), but no statistical significance was observed between the DRO group and the placebo group [34].”
BackgroundResultBelgers, V., Röttgering, J. G., Douw, L., Klein, M., Ket, J. C. F., van de Ven, P. M., Würdinger, T., Linde, M. E. V., Niers, J. M., Weber, M., et al. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0187 · Cited by 20
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
Maglaviceanu, A., Peer, M., Rockel, J. S., Bonin, R. P., Fitzcharles, M., Ladha, K. S., Bhatia, A., Leroux, T. S., Kotra, L. P., Kapoor, M., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01098-9 · Cited by 17
A Systematic Review of Medical Cannabinoids Dosing in Human
Campos, D. A., Mendivil, E. J., Romano, M., García, M., & Martínez, M. E. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.10.003 · Cited by 16
Cannabinoide reduzieren den Opioidverbrauch bei älteren Schmerzpatienten
Gastmeier, K., Gastmeier, A., Rottmann, F., Herdegen, T., & Böhm, R. (2022) · Der Schmerz · doi:10.1007/s00482-022-00642-0 · Cited by 11
Pressman, P., Hayes, A. W., Hoeng, J., Latino, D. A. R. S., Mazurov, A. A., Schlage, W. K., & Rana, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061540 · Cited by 13
A Practical Approach to Using Adjuvant Analgesics in Older Adults
Portenoy, R. K. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16340 · Cited by 13
An overview on disease modifying and symptomatic drug treatments for multiple sclerosis
Costa, G. D., Leocani, L., Rodegher, M., Chiveri, L. R., Gradassi, A., & Comi, G. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2410393 · Cited by 18
“It is more frequent in patients with progressive courses and may be long-lasting and severe [144–147].”
Echeverria-Villalobos, M., Fabian, C. A., Mitchell, J., Mazzota, E., Fiorda‐Diaz, J., Noon, K., & Weaver, T. E. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007313 · Cited by 11
Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis
Stefano, G. D., Stefano, G. D., Lionardo, A. D., Cruccu, G., & Truini, A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00731-7 · Cited by 12
Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer
Rower, J. E., King, A. D., Wilkins, D. G., Wilkes, J., Yellepeddi, V., Maese, L. D., Lemons, R. S., & Constance, J. E. (2020) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2020.0021 · Cited by 10
“Investigations are ongoing for THC use in the treatment of pain, anxiety, sleep disorders, depression, and various cancers.(1,13) Although THC has established a reasonably robust drug safety profile, there may be distinct risks or toxicities associated with THC use in children, such as an association with neurodevelop…”
BackgroundLiving Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Fu, R. F., Morasco, B. J., Kansagara, D. L., & Chou, R. (2021) · doi:10.23970/ahrqepccer250 · Cited by 12
Khan, M. G., Hussain, S. H. A., Alkhayl, F. F. A., Ahsan, M., & Ridha‐Salman, H. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04134-7 · Cited by 13
“…providers should carefully weigh the potential benefits against the risks of side effects and the individual patient's treatment history, highlighting the need for further research to establish the efficacy of dronabinol compared with other standard treatments for NP (Schimrigk et al. 2017).”
A Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030092 · Cited by 14
Cannabis-based medicines for chronic neuropathic pain in adults
Ateş, G., Welsch, P., Klose, P., Phillips, T., Lambers, B., Häuser, W., & Radbruch, L. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub3 · Cited by 20
Cannabis for Neuropathic Pain in Multiple Sclerosis—High Expectations, Poor Data
Rudroff, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01239 · Cited by 9
Pronounced State-Level Disparities in Prescription of Cannabinoids to Medicaid Patients
Liu, E. Y., McCall, K. L., & Piper, B. J. (2023) · Medical Cannabis and Cannabinoids · doi:10.1159/000531058 · Cited by 8
Lewis, M., Baroutian, S., & Hanning, S. M. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01196-1 · Cited by 11
Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use
Koch, C. D., Xu, L. Z., Curtis, S. A., Roberts, J. D., Bunch, D. R., & El-Khoury, J. M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.08.014 · Cited by 6
Matthiesen, S. T., Lunde, S. J., Kjær, S. W., Carlino, E., & Vase, L. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000717 · Cited by 7
Role of the Endocannabinoid System in Fibromyalgia
García‐Domínguez, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040230 · Cited by 9
“Similar to ajulemic acid, dronabinol is a potential candidate for treating the painful symptoms of fibromyalgia due to its foundation in alleviating symptoms associated with neuropathic pain [154].”
Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03152 · Cited by 4
Cannabinoide zur Therapie chronischer Nervenschmerzen und Spastik
Karst, M. (2022) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-022-0828-9 · Cited by 4
A Critical Systematic Review of Evidence for Cannabinoids in the Treatment of Schizophrenia
Sankaranarayanan, A., Wilding, H., Neill, E., & Castle, D. J. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180409-01 · Cited by 3
Johnson, M. B., McKnight, A. S., Taylor, E. P., Mechtler, L. L., & Ralyea, C. C. (2023) · Cannabis · doi:10.26828/cannabis/2023.01.002 · Cited by 3
Gaisey, J. N., & Narouze, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-69186-8_14 · Cited by 4
What's your cup of tea? The role of herbal compounds in the management of multiple sclerosis
Abdelgaied, M. Y., El‐Aziz, M. K. A., Amin, N. S., & Tayebi, H. M. E. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104799 · Cited by 3
Zertal, A., Marrouni, K. A., Arbour, N., Jutras‐Aswad, D., Pomey, M., Rouleau, I., Prat, A., Larochelle, C., Beaulieu, P., Chamelian, L., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1440678 · Cited by 7
Dronabinol as an answer to flavivirus infections: an in-silico investigation
Patar, A. K., Borah, S. M., Barman, J., Bora, A., & Baruah, T. J. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2160817 · Cited by 2
“Dronabinol belongs to the cannabinoid class of compounds, and it is a clinically prescribed compound used for issues ranging from neuropathic pain and cancer (Schimrigk et al., 2017, Bajtel et al., 2022).”
BackgroundCannabinoids in disorders of gut-brain interaction and gastrointestinal motility
Arboleda, M. F., Prosk, E., Watier, A., & Schmulson, M. J. (2021) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.20000021 · Cited by 3
Therapeutic Potential of Dronabinol: A Systematic Review of Human Trials
Lewandowska, J. A., Kapała, J. M., & Puchała, Ł. (2021) · Farmacja Polska · doi:10.32383/farmpol/142693 · Cited by 4
“Although the trial did not prove the effectiveness of the treatment, it demonstrated no signs of drug abuse and suggested that dronabinol is a safe long-term treatment option [31].”
BackgroundSchmerzen bei multipler Sklerose und Neuromyelitis-optica-Spektrum-Erkrankungen
Pellkofer, H., & Kümpfel, T. (2021) · Der Schmerz · doi:10.1007/s00482-021-00554-5 · Cited by 2
Chou, R., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., Selph, S., Holmes, R. S., & Fu, R. (2022) · doi:10.23970/ahrqepccannabissurveillance4 · Cited by 3
Cannabis products: medical use
Fernandes, C. E., Dolci, J. E. L., Navarro, L. S., Allevato, M., Constantino, C. F., Pereira, R. P. A., Rieder, C. R. D. M., Torino, F., Bernardo, W. M., & da Silva, A. G. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d693 · Cited by 2
Leppien, E. E., Pauling, E. E., Smith, E., Wisniewski, B., Carpenter, A., & Schwier, N. C. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2897 · Cited by 1
“31 Cannabinoid receptors are vastly expressed throughout the CV system and are known to cause direct and indirect interactions with the coagulation pathway.”
BackgroundThe clinical use of cannabinoids for pain
Simão, V. P., Tavares, G. M. Z., Santos, G. S., de Macedo, A. P., Azzini, G. O. M., Domingues, R. B., de Oliveira, R. C., Narche, L. D. S., da Fonseca, L. F., & Lana, J. F. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0754 · Cited by 1
“The consistent ingestion of dronabinol over an extended period suggested that tolerance to the drug did not develop [13].”
InfluentialSrinivasan, G., & Shukla, D. (2024) · INDIAN DRUGS · doi:10.53879/id.61.10.14528 · Cited by 2
Lane, R. M., Egan, L. J., McGuire, B. E., McKernan, D. P., O’Mahony, S. M., & Finn, D. P. (2025) · HRB Open Research · doi:10.12688/hrbopenres.14082.1 · Cited by 2
Mohamadi, M., Molla, A., Sadeghi, E., Orakifar, N., Bahari, M., Yekta, Z. M., Bervis, S., Hesampour, K., & Shokri, E. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106815 · Cited by 1
Pressman, P., & Hayes, A. W. (2025) · BJPsych Bulletin · doi:10.1192/bjb.2025.10183 · Cited by 1
Motamedy, S., Soltani, B., Kameshki, H., Kermani, A. A., Amleshi, R. S., Nazeri, M., & Shabani, M. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575285934240123110158 · Cited by 1
Metadata
- Authors
- Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D.
- Affiliations
- Klinikum Lüdenscheid (DE)
- Isar-Amper-Klinikum München-Ost (DE)
- Bionorica (Germany) (DE)
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 78
- Issue
- 5-6
- Pages
- 320-329
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- PMC
- PMC5804828
- OpenAlex
- W2765393731
- Cited by
- 136
- References
- 43
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 15 · 2023: 14 · 2022: 37 · 2021: 15 · 2020: 22 · 2019: 6 · 2018: 6
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- European Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer Vital
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- dronabinol, neuropathic pain, multiple sclerosis, cannabis-based treatment, long-term treatment safety, adverse drug reactions, drug addiction, pain intensity, risk-benefit ratio
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Dronabinol, Analgesics, Non-Narcotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.